Tratamiento actual más allá de las estatinas en la hipercolesterolemia: cuanto más bajo mejor en la prevención de las enfermedades ateroscleróticas
Author:
Publisher
GRAPHIMEDIC SA DE CV
Reference15 articles.
1. Choi JY, Na JO. Pharmacological strategies beyond statins: ezetimibe and PCSK9 inhibitors. J Lipid Atheroscler. 2019; 8 (2): 183-191.
2. Landmesser U, Chapman MJ, Stock JK, Amarenco P, Belch JJF, Borén J et al. 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. Eur Heart J. 2018; 39 (14): 1131-1143.
3. Ray KK, Corral P, Morales E, Nicholls SJ. Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options. Lancet. 2019; 394 (10199): 697-708.
4. Ma YB, Chan P, Zhang Y, Tomlinson B, Liu Z. Evaluating the efficacy and safety of atorvastatin + ezetimibe in a fixed-dose combination for the treatment of hypercholesterolemia. Expert Opin Pharmacother. 2019; 20 (8): 917-928.
5. Agarwala A, Kajani Z, Miedema MD, Virani SS. The role of ezetimibe in the treatment of cardiovascular disease. Curr Atheroscler Rep [Internet]. 2016; 18 (2). Available in: http://dx.doi.org/10.1007/s11883-016-0560-y
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3